Boldenone

Boldenone

Clinical data
Pregnancy category	X (US) X (AUS)
Routes of administration	Intramuscular
Legal status
Legal status	Schedule III (US) POM (UK)
Pharmacokinetic data
Elimination half-life	14 days
Identifiers
IUPAC name 3-[(8R,9S,10R,13S,14R,17R) -17-hydroxy-10,13-dimethyl-3-oxo-2,3,8,9,10,11,12,13,14,15,16,17- dodecahydro-1H-cyclopenta[a]phenanthren-17-yl] propanoic acid
CAS Number	846-48-0
PubChem CID	13308
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C19H26O2
Molar mass	286.409 g/mol
Melting point	165 °C (329 °F)

WikiDoc Resources for Boldenone
Articles
Most recent articles on Boldenone Most cited articles on Boldenone Review articles on Boldenone Articles on Boldenone in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Boldenone Images of Boldenone Photos of Boldenone Podcasts & MP3s on Boldenone Videos on Boldenone
Evidence Based Medicine
Cochrane Collaboration on Boldenone Bandolier on Boldenone TRIP on Boldenone
Clinical Trials
Ongoing Trials on Boldenone at Clinical Trials.gov Trial results on Boldenone Clinical Trials on Boldenone at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Boldenone NICE Guidance on Boldenone NHS PRODIGY Guidance FDA on Boldenone CDC on Boldenone
Books
Books on Boldenone
News
Boldenone in the news Be alerted to news on Boldenone News trends on Boldenone
Commentary
Blogs on Boldenone
Definitions
Definitions of Boldenone
Patient Resources / Community
Patient resources on Boldenone Discussion groups on Boldenone Patient Handouts on Boldenone Directions to Hospitals Treating Boldenone Risk calculators and risk factors for Boldenone
Healthcare Provider Resources
Symptoms of Boldenone Causes & Risk Factors for Boldenone Diagnostic studies for Boldenone Treatment of Boldenone
Continuing Medical Education (CME)
CME Programs on Boldenone
International
Boldenone en Espanol Boldenone en Francais
Business
Boldenone in the Marketplace Patents on Boldenone
Experimental / Informatics
List of terms related to Boldenone

Overview

Boldenone (1,4-androstadiene-3-one-17β-ol, available as the undecylenate ester), also known under the trade names Equipoise, Ganabol, Equigan and Ultragan, is an anabolic steroid developed for veterinary use, mostly for treatment of horses. It is not indicated for use in humans in the US and is only available through veterinary clinics.

The activity of boldenone is mainly anabolic, with a low androgenic potency. It has a very long half-life, and can show up on a steroid test for up to 5 months.

Boldenone will increase nitrogen retention, protein synthesis, increases appetite and stimulates the release of erythropoietin in the kidneys.

Because it has similar properties to methandienone (methylated boldenone), it is a favorite for adding strength and size. Boldenone is popular for bulking because it increases the appetite. Boldenone is well known for increasing vascularity.

Boldenone has a low rate of aromatization (about 50% of Testosterone), which means it does not convert to estrogen easily and does not cause very much water retention.

It is easily detectable in blood tests due to its long metabolic half-life. Trace amounts of the drug can easily be detected for months after discontinued use.

Side effects

Although commonly compared to nandrolone, boldenone lacks progesterone receptor interaction and all the associated progestinic side effects. Boldenone can, however, produce mild androgenic side effects. Oily skin, acne, increased aggression and hair loss are all possible with this compound but rare. Boldenone does reduce to a more potent androgen dihydroboldenone via the 5alpha-reductase enzyme (analogous to the conversion of testosterone to dihydrotestosterone (DHT), however its affinity for this interaction in the human body is low to nonexistent. Suppression of the HPTA, water retention, possible increase in acne and possible conversion to estrogen, high blood pressure are all side effects associated with Boldenone. Boldenone is also known to cause anxiety and flu like symptoms which manifest themselves most acutely in short ester versions like: acetate, and propionate (almost unusable), but which are also present in the enanthate, cypionate, and undecyclenate forms.

References

Template:WikiDoc Sources